NO20072747L - Fremgangsmate for fremstilling av indazolforbindelser - Google Patents

Fremgangsmate for fremstilling av indazolforbindelser

Info

Publication number
NO20072747L
NO20072747L NO20072747A NO20072747A NO20072747L NO 20072747 L NO20072747 L NO 20072747L NO 20072747 A NO20072747 A NO 20072747A NO 20072747 A NO20072747 A NO 20072747A NO 20072747 L NO20072747 L NO 20072747L
Authority
NO
Norway
Prior art keywords
preparation
compounds
formula
indazole compounds
protein kinases
Prior art date
Application number
NO20072747A
Other languages
English (en)
Inventor
Bing Shi
Qingping Tian
Babu Srinivasan
Jr Raymond Dagnino
Michael Allen Ouelette
Scott Edward Zook
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20072747L publication Critical patent/NO20072747L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelsen angår fremgangsmåter for fremstilling av indasolforbindelser som har formel (I) eller farmasøytisk akseptable salter eller solvater derav. Forbindelser med formel (I) er anvendelige som antiangiogenesemidler og som midler for å modulere og/eller inhibere aktiviteten til proteinkinaser, som således tilveiebringer behandlinger for kreft eller andre sykdommer assosiert med cellulær proliferasjon mediert av proteinkinaser.
NO20072747A 2004-11-02 2007-05-30 Fremgangsmate for fremstilling av indazolforbindelser NO20072747L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62457504P 2004-11-02 2004-11-02
PCT/IB2005/003300 WO2006048745A1 (en) 2004-11-02 2005-10-21 Methods for preparing indazole compounds

Publications (1)

Publication Number Publication Date
NO20072747L true NO20072747L (no) 2007-07-31

Family

ID=35528034

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072747A NO20072747L (no) 2004-11-02 2007-05-30 Fremgangsmate for fremstilling av indazolforbindelser

Country Status (15)

Country Link
EP (1) EP1809625A1 (no)
JP (1) JP2008518901A (no)
KR (1) KR20070058689A (no)
CN (1) CN101044138A (no)
AR (1) AR051753A1 (no)
AU (1) AU2005300311A1 (no)
BR (1) BRPI0517921A (no)
CA (1) CA2586176A1 (no)
IL (1) IL182096A0 (no)
MX (1) MX2007003603A (no)
NO (1) NO20072747L (no)
RU (1) RU2007114112A (no)
TW (1) TW200614990A (no)
WO (1) WO2006048745A1 (no)
ZA (1) ZA200702317B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
CN101679356A (zh) 2007-04-05 2010-03-24 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-（甲基-氨甲酰基）苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
TW201531309A (zh) 2011-09-30 2015-08-16 Pfizer Ｎ-甲基-２-〔３-（（ｅ）-２-吡啶-２-基-乙烯基）-１ｈ-吲唑-６-基硫烷基〕苯甲醯胺之藥學組成物
JP2014533262A (ja) 2011-11-11 2014-12-11 ファイザー・インク 慢性骨髄性白血病を治療するためのｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミド
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN103387565B (zh) * 2013-07-29 2014-10-29 苏州明锐医药科技有限公司 阿西替尼的制备方法
CN103570696B (zh) * 2013-11-06 2016-02-24 湖南欧亚生物有限公司 一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
RU2667486C2 (ru) * 2014-03-31 2018-09-20 Сэндзю Фармацевтикал Ко., Лтд. Производное алкинилиндазола и его применение
CN104072484B (zh) * 2014-07-07 2016-07-06 渤海大学 氮-(4-(芳巯基)-1氢-吲唑-3-基)-1-(芳杂环取代)甲基亚胺类化合物及其药学上可接受的盐及其制备方法和应用
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
KR20170132171A (ko) 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 ｐｄ­１ ／ ｐｄ­ｌ１ 저해제
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
ES2982700T3 (es) 2019-04-18 2024-10-17 Synthon Bv Proceso para preparar axitinib, proceso para purificar el producto intermedio 2-((3-yodo-1H-indazol-6-il)tio)-n-metilbenzamida, proceso para purificar axitinib a través de la sal HCI de axitinib, forma sólida de la sal HCI de axitinib
CN112209861A (zh) * 2019-07-11 2021-01-12 鲁南制药集团股份有限公司 一种阿昔替尼中间体化合物及其制备方法
CN112442010B (zh) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 一类前药化合物及其在治疗癌症方面的应用
CN111440102B (zh) * 2020-04-26 2022-02-15 大连凯飞化学股份有限公司 一种二硫代二苯甲酰胺类化合物的制备方法
IL315262A (en) 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
US20260049071A1 (en) * 2022-08-08 2026-02-19 Beyang Therapeutics Co., Ltd. Protein tyrosine kinase inhibitor and medical use thereof
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
AU2003286321A1 (en) * 2002-12-19 2004-07-14 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
KR101099281B1 (ko) * 2003-03-03 2011-12-26 어레이 바이오파마 인크. ｐ38 억제제 및 그의 사용 방법
WO2005094823A1 (ja) * 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Ｆｌｔ－３阻害剤

Also Published As

Publication number Publication date
TW200614990A (en) 2006-05-16
MX2007003603A (es) 2007-05-21
JP2008518901A (ja) 2008-06-05
CA2586176A1 (en) 2006-05-11
ZA200702317B (en) 2008-09-25
RU2007114112A (ru) 2008-12-10
CN101044138A (zh) 2007-09-26
KR20070058689A (ko) 2007-06-08
EP1809625A1 (en) 2007-07-25
IL182096A0 (en) 2007-07-24
WO2006048745A1 (en) 2006-05-11
AR051753A1 (es) 2007-02-07
AU2005300311A1 (en) 2006-05-11
BRPI0517921A (pt) 2008-10-21

Similar Documents

Publication Publication Date Title
MX2007003603A (es) Metodos para preparar compuestos de indazol.
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20081454L (no) Met-kinaseinhibitorer
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
NO20061743L (no) Kinazolinderivater
NO20064895L (no) 6,6-Bisykliske ring-substituerte heterobisykliske protein-kinase inhibitorer
NO20061194L (no) Mitotiske kinesininbibitorer
NO20083214L (no) Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20061327L (no) Kinazolinderivater
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20063449L (no) Substituerte heterocykler og deres anvendelse
YU84603A (sh) Novi inhibitori tirozin kinaze
NO20070917L (no) Imidazotriaziner som protein-kinaseinhibitorer
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
NO20091708L (no) Nye kinase inhibitorer
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application